Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells

G Schreibelt, KF Bol, H Westdorp, F Wimmers… - Clinical cancer …, 2016 - AACR
Purpose: Thus far, dendritic cell (DC)-based immunotherapy of cancer was primarily based
on in vitro–generated monocyte-derived DCs, which require extensive in vitro manipulation. …

[HTML][HTML] Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens

H Westdorp, AE Sköld, BA Snijer, S Franik… - Frontiers in …, 2014 - frontiersin.org
Prostate cancer (PCa) is the most common cancer in men and the second most common
cause of cancer-related death in men. In recent years, novel therapeutic options for PCa have …

[HTML][HTML] Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre) clinical studies

…, J Nagarajah, S Heskamp, H Westdorp - European journal of …, 2023 - Springer
Introduction Fibroblast activation protein (FAP) is highly overexpressed in stromal tissue of
various cancers. While FAP has been recognized as a potential diagnostic or therapeutic …

[HTML][HTML] Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant …

H Westdorp, JHA Creemers, IM van Oort… - … for immunotherapy of …, 2019 - Springer
Background Clinical benefit of cellular immunotherapy has been shown in patients with
castration-resistant prostate cancer (CRPC). We investigated the immunological response and …

[HTML][HTML] Opportunities for immunotherapy in microsatellite instable colorectal cancer

H Westdorp, FL Fennemann, RDA Weren… - Cancer Immunology …, 2016 - Springer
Microsatellite instability (MSI), the somatic accumulation of length variations in repetitive DNA
sequences called microsatellites, is frequently observed in both hereditary and sporadic …

[HTML][HTML] Mechanisms of immune checkpoint inhibitor-mediated colitis

H Westdorp, MWD Sweep, MAJ Gorris… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have provided tremendous clinical benefit in several
cancer types. However, systemic activation of the immune system also leads to several immune-…

[HTML][HTML] Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

…, M Bloemendal, N de Haas, H Westdorp… - Cancer Immunology …, 2020 - Springer
Background Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but
their effect can be counteracted by immunosuppressive mechanisms. Cisplatin has shown …

[HTML][HTML] Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome

H Westdorp, S Kolders, N Hoogerbrugge, IJM de Vries… - Cancer letters, 2017 - Elsevier
Monoallelic germline mutations in one of the DNA mismatch repair (MMR) genes cause
Lynch syndrome, with a high lifetime risks of colorectal and endometrial cancer at adult age. …

[PDF][PDF] Combining targeted radionuclide therapy and immune checkpoint inhibition for cancer treatment

…, E Oosterwijk, J Bussink, H Westdorp… - Clinical Cancer …, 2022 - AACR
The development of immunotherapy, in particular immune checkpoint inhibitors (ICI), has
revolutionized cancer treatment in the past decades. However, its efficacy is still limited to …

Adjuvant dendritic cell vaccination in high-risk uveal melanoma

…, E Kiliç, WJ Japing, KW Geul, H Westdorp… - …, 2016 - aaojournal.org
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults with an
annual incidence of 4 to 10 per million in the white population. The 5-year overall survival (…